ProfileGDS5678 / 1451193_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 66% 71% 70% 72% 72% 68% 73% 76% 72% 70% 71% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6122272
GSM967853U87-EV human glioblastoma xenograft - Control 23.9745566
GSM967854U87-EV human glioblastoma xenograft - Control 34.5061171
GSM967855U87-EV human glioblastoma xenograft - Control 44.4954570
GSM967856U87-EV human glioblastoma xenograft - Control 54.5744872
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.518672
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2268
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6597573
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1102676
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6218772
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3489870
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4586671
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.479871
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4986271